There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viveve Medical Inc (NASDAQ: VIVE) and AstraZeneca (NYSE: AZN) with bullish sentiments.
Viveve Medical Inc (NASDAQ: VIVE)
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Viveve Medical Inc (NASDAQ: VIVE), with a price target of $4. The company’s shares opened today at $2.55, close to its 52-week low of $2.01.
Yang observed:
“We see elevated execution risk at a crucial stage of development for the company. Despite all the headwinds, we still like the technology, favorable demographics and the attractive valuation. We maintain our Buy rating and reduce our PT from $10 to $4.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.6% and a 48.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Viveve Medical Inc is Strong Buy and the average price target is $9, representing a 252.9% upside.
In a report released today, Maxim Group also maintained a Buy rating on the stock with a $9 price target.
See today’s analyst top recommended stocks >>
AstraZeneca (NYSE: AZN)
BMO Capital analyst Alex Arfaei maintained a Buy rating on AstraZeneca (NYSE: AZN) today and set a price target of $40. The company’s shares opened today at $36.25, close to its 52-week high of $36.75.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 4.6% and a 63.0% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.
AstraZeneca has an analyst consensus of Moderate Buy, with a price target consensus of $40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
